Prime Medicine (PRME) Free Cash Flow (2021 - 2026)

Prime Medicine (PRME) has 6 years of Free Cash Flow data on file, last reported at -$42.7 million in Q1 2026.

• Quarterly Free Cash Flow rose 16.71% year-over-year to -$42.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$158.5 million (down 48.49% YoY) and the FY2025 annual result came in at -$167.1 million, down 34.73% from the prior year.
• Free Cash Flow declined to -$42.7 million in Q1 2026, from -$37.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $15.2 million in Q4 2024 to a low of -$68.5 million in Q1 2024.
• A 5-year average of -$37.7 million and a median of -$39.1 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2024 — Free Cash Flow soared 129.19% — and 2025, when it tumbled 346.98%.
• Tracing PRME's Free Cash Flow over 5 years: stood at -$20.4 million in 2022, then tumbled by 155.26% to -$52.1 million in 2023, then soared by 129.19% to $15.2 million in 2024, then sank by 346.98% to -$37.5 million in 2025, then dropped by 13.75% to -$42.7 million in 2026.
• The last three Free Cash Flow figures came in at -$42.7 million (Q1 2026), -$37.5 million (Q4 2025), and -$39.1 million (Q3 2025), per Business Quant data.